Clinical trials: Induced Pluripotent Stem Cell (Ips Cell)
Type 1 Diabetes
Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes
Clinically, the ability to slow or prevent beta cell demise can prevent or improve the course of type 1 diabetes. The immune-mediated destruction of beta cells that is an apparent major pathological basis for the disease, has led…
- Trial name
- NCT02218619
- Testing
- Tauroursodeoxycholic Acid (TUDCA)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Robin Goland, MD
Cystic Fibrosis
Trikafta in Cystic Fibrosis Patients
This clinical study will enroll 42 participants without the F508del mutation, carrying partial function or N1303K mutations not approved for Trikafta, and who are not expected to be approved for CFTR modulator treatment in the…
- Trial name
- NCT03506061
- Testing
- Trikafta
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Emory University